BioCentury
ARTICLE | Company News

Annapurna Therapeutics, Avalanche Biotechnologies deal

February 8, 2016 8:00 AM UTC

Avalanche will acquire Annapurna, gaining four preclinical adeno-associated virus (AAV) gene therapy programs. The programs include ANN-001, an AAV vector delivering alpha-1 antitrypsin ( AAT; A1AT; SERPINA1) to treat AAT deficiency; ANN-002, an AAV vector to treat hereditary angioedema (HAE); ANN-003, an AAV serotype 10 (AAV10) vector delivering the human frataxin ( FXN; FRDA) gene to treat Friedreich’s ataxia; and ANN-004, an AAV vector to treat severe allergies. Annapurna has exclusive rights to ANN-001, ANN-002 and ANN-004 from Weill Cornell Medical College (New York, N.Y.). ...